NEW YORK, Sept. 19, 2006 (PRIMEZONE) -- Manhattan Pharmaceuticals, Inc. (AMEX:MHA) today announced that Alan G. Harris, MD, PhD, the company's Chief Medical Officer, will chair the upcoming two-day Metabolic Syndrome Conference: Achieving Successful Drug Approval While Seizing Untapped Commercial Opportunities. The event will be held September 26-27 at the Radisson Hotel Boston in Boston, MA.
In addition to his leadership responsibilities at the conference, Dr. Harris will participate as a panelist in the closing session titled: "Opportunities and Challenges for Future Treatments of the Metabolic Syndrome," which will be held Wednesday, September 27 at 3:45pm EDT.
Other expert speakers to be featured at the conference include: Douglas Greene, MD, Chief Medical Officer, sanofi-aventis; Rebecca Taub, MD, VP Research-Metabolic Diseases, Hoffman La-Roche; Tu Nguyen, MD, Director-Cardiovascular, Metabolic & Endocrine Diseases, Pfizer Global Research & Development; Pierre Rosensweig, MD, VP-Internal Medicine Clinical Development, sanofi-aventis; Karsten Wassermann, PhD, DSc, Project VP-Clinical Development, Medical & Regulatory Affairs, Novo Nordisk; and David V. Erbe, PhD, Cardiovascular & Metabolic Diseases, Wyeth Research.
To learn more about the conference, or to request a brochure, please go to http://www.marcusevans.com/events/CFEventinfo.asp?EventID=10903 or visit the Manhattan Pharmaceuticals, Inc. website at http://www.manhattanpharma.com.
About Manhattan Pharmaceuticals, Inc.
Manhattan Pharmaceuticals, Inc., a development-stage pharmaceutical company, acquires and develops proprietary prescription drugs for large, underserved patient populations. In view of the worldwide obesity epidemic, the company is developing OE, an orally administered novel therapeutic for the treatment of obesity. To meet the needs of other major, underserved medical markets while lowering development risks, Manhattan Pharmaceuticals is also developing PTH (1-34), a peptide believed to be a regulator of epidermal cell growth, for psoriasis, and Propofol Lingual Spray, a convenient, proprietary lingual spray formulation of propofol, the world's best-selling general anesthetic, as a sedative-hypnotic for use during diagnostic and therapeutic procedures. (http://www.manhattanpharma.com)
Note Regarding Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are valid only as of today, and we disclaim any obligation to update this information. These statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on our current beliefs and expectations as to such future outcomes. Drug discovery and development involve a high degree of risk. Factors that might cause such a material difference include, among others, uncertainties related to the ability to attract and retain partners for our technologies, the identification of lead compounds, the successful preclinical development thereof, the completion and results of clinical trials, including clinical trials involving oleoyl-estrone, the FDA review process and other governmental regulation, our pharmaceutical collaborator's ability to successfully develop and commercialize drug candidates, issues relating to drug formulation and manufacturing, competition from other pharmaceutical companies, product pricing and third party reimbursement, and other factors described in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-KSB for the year ended December 31, 2005. The Company assumes no obligation to update these statements, except as required by law.